Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Post by mstrmndon Jan 22, 2021 4:44pm
418 Views
Post# 32362218

Probability of Positive ROI with ATE - Jan 22. Market Close

Probability of Positive ROI with ATE - Jan 22. Market CloseHi longs, 

Curious as to what the almost insiders that know this company inside out think of the following from the current entry point today (say $4.00 to keep round numbers): 

Projected 1-year ROI  =  
Projected 3-year ROI  = 
Projected 5-year ROI  = 

Based on your calculated risk, kindly state probability of achieving projected ROIs (low, average, or high probability).

From a tax efficiency prespective, is it fair to say, ATE.TO via TFSA, RRSP, or other tax efficient vehicle could be one of the best Canadian companies to invest in right now for investors looking long-term?  Where if you can afford to hold for 3-5 years, it is a very low risk investment with a tremendous short-term and long-term upside?

On my assessment it looks like the long-term ROI is in the range of 10x to 300x+ from market close January 22, 2021, where after the COVID storm, there will be a natural lift on NASDAQ timed to capital markets where Antibe Holdings will be pursuing multiple lines of therapeutics in their pipeline in the following markets:
1. Chronic Pain (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis)
2. Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease)

Will we see a jump in the SP once amalgamated with Antibe Holdings, because now the key has opened the lock where the combined entity value jumps (amalgamation, market marker opens at new SP)? 

Have a great weekend everyone!  GLTA
<< Previous
Bullboard Posts
Next >>